Experience with extracoporeal elimination therapy in myasthenia gravis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F11%3A43874731" target="_blank" >RIV/60162694:G44__/11:43874731 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.transci.2011.10.003" target="_blank" >http://dx.doi.org/10.1016/j.transci.2011.10.003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.transci.2011.10.003" target="_blank" >10.1016/j.transci.2011.10.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Experience with extracoporeal elimination therapy in myasthenia gravis

Popis výsledku v původním jazyce

We describe our experience with plasma exchange (PE) and immunoadsorption in patients with myasthenia gravis. The group of 27 patients consists of 21 patients treated with PE and 6 patients who received immunoadsorption. PE therapy led to stabilization in 20 patients. In patients treated with immunoadsorption, therapy could be discontinued in 2 patients after 13 months of therapy, and the other 4 patients were stabilized without myasthenic crises after 6-9 years of therapy. Extracorporeal elimination therapy through PE or immunoadsorption is effective and sometimes life saving and is safe in the hands of an experienced team (6% complication rate). (C) 2011 Elsevier Ltd. All rights reserved.

Název v anglickém jazyce

Experience with extracoporeal elimination therapy in myasthenia gravis

Popis výsledku anglicky

We describe our experience with plasma exchange (PE) and immunoadsorption in patients with myasthenia gravis. The group of 27 patients consists of 21 patients treated with PE and 6 patients who received immunoadsorption. PE therapy led to stabilization in 20 patients. In patients treated with immunoadsorption, therapy could be discontinued in 2 patients after 13 months of therapy, and the other 4 patients were stabilized without myasthenic crises after 6-9 years of therapy. Extracorporeal elimination therapy through PE or immunoadsorption is effective and sometimes life saving and is safe in the hands of an experienced team (6% complication rate). (C) 2011 Elsevier Ltd. All rights reserved.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Transfusion and Apheresis Science

ISSN

1473-0502

e-ISSN

—

Svazek periodika

45

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

251-256

Kód UT WoS článku

000299141100006

EID výsledku v databázi Scopus

—